Active, not recruitingPhase 3NCT05933200
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
Studying 3-hydroxyacyl-CoA dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Medical DirectorUltragenyx Pharmaceutical Inc
- Intervention
- Triheptanoin(drug)
- Enrollment
- 69 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2023 – 2027
Study locations (15)
- General University Hospital in Prague-GUH (Všeobecná fakultní nemocnice v Praze- VFN), Prague, Czechia
- Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
- Juntendo University Hospital, Bunkyo City, Tokyo, Japan
- The Jikei University Hospital, Minato, Tokyo, Japan
- Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw, Masovian Voivodeship, Poland
- Gdańksi Uniwersytet Medyczny, Gdansk, Pomeranian Voivodeship, Poland
- King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
- Sant Joan de Deu Hospital (SJD), Barcelona, Esplugues de Llobregat, Spain
- University Hospital Santiago de Compostela, A Coruña, Spain
- University Hospital 12 de Octubre, Madrid, Spain
- Cukurova University, Adana, Turkey (Türkiye)
- Gazi University, Ankara, Turkey (Türkiye)
- Ege University, Bornova-İzmir, Turkey (Türkiye)
- Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey (Türkiye)
- Cerrahpasa Medical Faculty, Istanbul, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05933200 on ClinicalTrials.govOther trials for 3-hydroxyacyl-CoA dehydrogenase deficiency
Additional recruiting or active studies for the same condition.
See all trials for 3-hydroxyacyl-CoA dehydrogenase deficiency →